Targeted Protein Degradation for Neurodegenerative Diseases
Overview
flowchart TD
Targeted_Protein_Degradation_f["Targeted Protein Degradation for Neurodegenerati"]
Targeted_Protein_Degradation_f["Neurodegenerative"]
Targeted_Protein_Degradation_f -->|"related to"| Targeted_Protein_Degradation_f
style Targeted_Protein_Degradation_f fill:#81c784,stroke:#333,color:#000
Targeted_Protein_Degradation_f["table"]
Targeted_Protein_Degradation_f -->|"related to"| Targeted_Protein_Degradation_f
style Targeted_Protein_Degradation_f fill:#81c784,stroke:#333,color:#000
Targeted_Protein_Degradation_f["class"]
Targeted_Protein_Degradation_f -->|"related to"| Targeted_Protein_Degradation_f
style Targeted_Protein_Degradation_f fill:#81c784,stroke:#333,color:#000
style Targeted_Protein_Degradation_f fill:#4fc3f7,stroke:#333,color:#000
...
Targeted Protein Degradation for Neurodegenerative Diseases
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-therapeutic">
Targeted protein degradation represents a paradigm shift in drug discovery, offering a novel therapeutic approach that eliminates disease-causing proteins rather than simply inhibiting their function. Using the cell's natural degradation machinery—particularly the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system)—degrader molecules can induce the destruction of specific proteins that have been considered "undruggable" by traditional approaches["@bks2022"]. While still in early development for neurodegenerative diseases, this modality has achieved multiple approvals in oncology, validating the platform and generating significant interest for CNS applications.
Mechanism of Action
PROTACs (Proteolysis-Targeting Chimeras) PROTACs are bifunctional molecules with two distinct binding domains connected by a linker:
Target-binding domain : Binds the protein of interestE3 ligase-binding domain : Recruits an E3 ubiquitin ligaseLinker : Connects the two domainsThe resulting ternary complex brings the target protein into proximity with the E3 ligase, leading to[@paiva2019]:
Transfer of ubiquitin molecules to the target protein
Recognition by the proteasome
Degradation of the target protein
Key advantage:
Substoichiometric activity — one PROTAC molecule can catalyze the destruction of multiple target molecules.
Molecular Glues Molecular glues are smaller monovalent molecules that:
Stabilize interactions between a target protein and an E3 ligase
Induce degradation without bivalent architecture
Typically have better drug-like properties than PROTACs
Examples: Thalidomide analogs (lenalidomide, pomalidomide) induce degradation of IKZF1, IKZF3, and other proteins.
Other Approaches
[Autophagy](/entities/autophagy)-targeting chimeras (AUTAC) : Engage autophagy machineryMolecular degraders of specific proteins : Optimized for CNS targetsHybrid approaches : Combining degradation with other mechanismsClinical Programs
Neurodegeneration Programs While still preclinical, several programs are advancing:
Emerging Targets
Tau : Most advanced CNS degrader programAlpha-synuclein : Parkinson's disease targetTDP-43 : ALS and FTD target[Huntingtin](/proteins/huntingtin) : Huntington's disease targetAdvantages
Substoichiometric Activity
One degrader molecule can eliminate multiple target proteins
Catalytic mechanism enables potent effects at low concentrations
May overcome some resistance mechanisms
"Undruggable" Target Access
Can target proteins without defined binding pockets
Enzymes, scaffolding proteins, transcription factors
Proteins resistant to traditional inhibition
Reversible Effects
Protein levels recover after treatment cessation
Allows treatment interruption
Useful for safety assessment
Novel Mechanism of Action
Different from existing drugs
May bypass resistance to inhibitors
Can address gain-of-function toxicities
Limitations
CNS Delivery Challenges
Large molecular weight (>500 Da) limits [BBB](/entities/blood-brain-barrier) penetration
Requires specialized brain-penetrant designs
May require invasive delivery
New Modality Risks
Limited clinical experience in CNS
Unexpected toxicities possible
Long-term consequences unknown
E3 Ligase Dependency
Limited to E3 ligases with suitable cereblon (CRBN) or VHL binding
Not all target/ligase combinations work
May need to identify new E3 ligases
Safety Concerns
Off-target degradation possible
Ubiquitin system disruption
Unknown consequences of chronic degradation
Duration of Effect
May require continuous dosing
Drug half-life considerations
Resistance development possible
Design Considerations
Molecular Weight
Typical PROTACs: 600-1000+ Da
Challenge for CNS penetration
Brain-penetrant designs under development
Linker Optimization
Length affects ternary complex formation
Flexibility impacts target engagement
PEG linkers common
E3 Ligase Selection
CRBN (cereblon): Most common, thalidomide-derived
VHL: Well-characterized
cIAP1: Cancer applications
CNS-appropriate: Identifying new ligases
Target Selection
Gain-of-function toxicities ideal
Knockdown is beneficial
Scaffolding functions addressable
Future Directions
Brain-Penetrant Degraders
Reducing molecular weight
Designing CNS-optimized compounds
Prodrug approaches
New E3 Ligases
Identifying ligases with brain expression
Engineering new ligase binders
Tissue-specific degradation
Combination Approaches
Degrader + antibody
Degrader + ASO
Multiple degraders
Protein-Specific Advances
Tau degradation : Most advanced programAlpha-synuclein : Significant interestTDP-43 : Emerging targetLRRK2 : Parkinson's applicationsComparison with Other Modalities
Cross-Links
[Therapeutic Modalities Overview](/therapeutics/therapeutic-modalities)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Tau Protein](/proteins/tau)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
See Also
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: The past is prologue (2022)](https://doi.org/10.1038/s41573-021-00371-4)
[Unknown, Paiva, S. L., & Crews, C. M. (2019). Targeted protein degradation: Elements of the next drug discovery era (2019)](https://doi.org/10.1016/j.cbpa.2019.02.011)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
[Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
[Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
[Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
[Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
[Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
Related Analyses:
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
Show full description